Case Number: UA13-138

InventionThis technology develops a material platform that utilizes a cholesterol-based material, cholesteryl-succinyl silane (CSSl), that when organized into particular nanostructures is able to minimize protein denaturation and optimize antibody orientation. Using nanostructured cholesterol-based materials results in an improved way by which to immobilize antibodies and veer away from the current commercial dependence on the immobilization of antibodies based on hydrophobic interactions.BackgroundAntibodies can be used to detect the presence of numerous antigens. However, antibodies must maintain proper orientation and conformation in order to interact with the target in question. Commercially available platforms that use antibodies still rely heavily on hydrophobic interactions, denaturing the vast majority of the antibodies and leaving only a fraction of antibodies able to interact with the antigen. Applications: This product can potentially be used to minimize protein denaturation and optimize antibody orientation for use in antibody/antigen applications.AdvantagesFunctional steroid tails are available for anchoring antibodies.Minimize the risk of protein denaturation and optimized antibody orientation.Can be hydrolyzed and polymerized.Allows for more sensitive means by which to identify (and potentially filter) antigens out of samples.ApplicationsCan be incorporated into existing VP stents and drug delivery systemsGive constant readings on flow volume without the need for invasive surgery or having to wait for complications to ariseInventorXiaoyi Wu ContactRobert SleeperLicensing Manager, Tech Launch ArizonaRobertS@tla.arizona.eduO: 520-626-4604

USA